Ralliant (NYSE:RAL) Releases FY 2026 Earnings Guidance

Ralliant (NYSE:RAL) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.530-2.690 for the period, compared to the consensus estimate of 2.350. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion. Ralliant also updated its Q2 2026 guidance to 0.580-0.640 EPS.

Ralliant Trading Up 4.5%

Shares of Ralliant stock opened at $49.36 on Tuesday. The firm has a 50-day moving average of $44.32 and a 200-day moving average of $47.07. The stock has a market cap of $5.52 billion and a PE ratio of 25.18. Ralliant has a 52-week low of $37.27 and a 52-week high of $57.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.58 and a current ratio of 0.84.

Ralliant (NYSE:RAL) last announced its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter. The business had revenue of $534.60 million during the quarter. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, sell-side analysts forecast that Ralliant will post 2.37 EPS for the current year.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 8th. Ralliant’s payout ratio is presently 10.20%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on RAL shares. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Zacks Research raised shares of Ralliant from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Citigroup cut their price objective on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Morgan Stanley reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Ralliant in a research report on Friday, February 6th. Finally, Truist Financial cut their price objective on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.50.

Insider Buying and Selling

In other Ralliant news, SVP Karen M. Bick sold 5,485 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total transaction of $246,825.00. Following the completion of the transaction, the senior vice president owned 46,756 shares of the company’s stock, valued at approximately $2,104,020. The trade was a 10.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Dodge & Cox raised its stake in Ralliant by 13.3% during the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after acquiring an additional 1,434,376 shares in the last quarter. Viking Global Investors LP acquired a new position in Ralliant during the second quarter worth about $257,200,000. State Street Corp acquired a new position in Ralliant during the second quarter worth about $213,096,000. Invesco Ltd. raised its stake in Ralliant by 4.9% during the fourth quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock worth $206,674,000 after acquiring an additional 187,898 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. increased its stake in shares of Ralliant by 19.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,423,268 shares of the company’s stock valued at $174,279,000 after buying an additional 563,822 shares during the period.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.